ConductScience.org, home

Paper39720556

Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.

Zhang D and 7 others. Front Chem, 2024. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Recent advances in the treatment of non-small cell lung cancer with MET inhibitors. Papers, record 39720556. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39720556

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.
PubMed
Journal
Front Chem
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.83, provisional
iCite
Revised in PubMed
2025-01-04
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang DDongna
2Zhang WWenying
3Liu HHe
4Liu PPan
5Li CChunxin
6Liu YYangyang
7Han JJicheng
8Zhu GGuangze

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References104

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
223944843
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
J Med Chem2013https://conductscience.org/library/papers/23944843PubMed
332034073Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.Clin Cancer Res2020https://conductscience.org/library/papers/32034073PubMed
438074469Structural insight into the macrocyclic inhibitor TPX-0022 of c-Met and c-Src.Comput Struct Biotechnol J2023https://conductscience.org/library/papers/38074469PubMed
534076436Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors.J Med Chem2021https://conductscience.org/library/papers/34076436PubMed
634391508Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.Lancet Oncol2021https://conductscience.org/library/papers/34391508PubMed
733666419Structure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors.J Med Chem2021https://conductscience.org/library/papers/33666419PubMed
834804015Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?Front Immunol2021https://conductscience.org/library/papers/34804015PubMed
929157685Recent advances in the discovery of small molecule c-Met Kinase inhibitors.Eur J Med Chem2018https://conductscience.org/library/papers/29157685PubMed
1036843841Tivantinib alleviates inflammatory diseases by directly targeting NLRP3.iScience2023https://conductscience.org/library/papers/36843841PubMed
1138239394Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.Cancer Drug Resist2023https://conductscience.org/library/papers/38239394PubMed
1230909397C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.Cells2019https://conductscience.org/library/papers/30909397PubMed
1338430418MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study.Clin Transl Oncol2024https://conductscience.org/library/papers/38430418PubMed
1432432477Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.J Med Chem2020https://conductscience.org/library/papers/32432477PubMed
1534663410Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.J Exp Clin Cancer Res2021https://conductscience.org/library/papers/34663410PubMed
1632479794
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Lancet Respir Med2020https://conductscience.org/library/papers/32479794PubMed
1716052207Hepatocyte growth factor promotes lymphatic vessel formation and function.EMBO J2005https://conductscience.org/library/papers/16052207PubMed
1829990309Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.J Clin Invest2018https://conductscience.org/library/papers/29990309PubMed
1938386085MET receptor serves as a promising target in melanoma brain metastases.Acta Neuropathol2024https://conductscience.org/library/papers/38386085PubMed
2031227004MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.J Hematol Oncol2019https://conductscience.org/library/papers/31227004PubMed

See all 104 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42597321MAML-residual transformer for few-shot prediction of targeted therapy response in NSCLC.Front Cell Dev Biol2026https://conductscience.org/library/papers/42597321PubMed
40641110MicroRNA‑21: A potential therapeutic target in lung cancer (Review).Int J Oncol2025https://conductscience.org/library/papers/40641110PubMed
40289194The role of Wnt/β-catenin signaling in lung cancer progression and therapy: a comprehensive review.Med Oncol2025https://conductscience.org/library/papers/40289194PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39720556

GET https://conductscience.org/api/papers/v1/39720556/references?page=2